Lantheus Medical Imaging, Inc. ("Lantheus") today announced that it intends to offer (the "Offering") $150 million in aggregate principal amount of its 9.750% Senior Notes due 2017 (the "New Notes"). The New Notes are being offered as additional debt securities under an indenture (the "Indenture") pursuant to which Lantheus previously issued $250 million in aggregate principal amount of 9.750% Senior Notes due 2017. Lantheus intends to use the net proceeds of the Offering to, among other things, (i) make a distribution to its ultimate parent company, Lantheus MI Holdings, Inc. ("Holdings"), to allow it to repurchase the remainder of its outstanding preferred stock and to pay a dividend to its common security holders and (ii) pay related fees and expenses.
The New Notes will be senior unsecured obligations of Lantheus and will be guaranteed on a senior basis by Lantheus MI Intermediate, Inc., Lantheus' parent company, and all of its current and future wholly-owned domestic subsidiaries. The Offering is subject to customary conditions, and there can be no assurances that the Offering will be consummated.
The New Notes have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any other jurisdiction. As a result, they may not be offered or sold in the United States or to any U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The New Notes will be offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside the United States under Regulation S under the Securities Act.